Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Redefining Hepatitis B Disease Management with DLI's drug insights, pipeline assessment, and clinical trial management endeavours| Disease Landscape Insights

This image opens in the lightbox

News provided by

Disease Landscape Insights

10 Oct, 2023, 08:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Oct. 10, 2023 /PRNewswire/ -- Hepatitis B is a type of viral infection that typically affects the liver. According to an epidemiology study by the CDC, this disease is the cause of nearly 820,000 deaths every year. The growing disease burden is indeed a cause of global concern given the severity of hepatitis b complications.

Hepatitis B is predominantly caused by the HBV virus. It is known to cause severe damage of the liver leading to the occurrence of both acute and chronic liver disease. Timeline hepatitis b prognosis acts as a boon for the patients. Early diagnosis helps doctors to strategize effective treatment plans before it gets too late. By providing the ideal hepatitis b treatment options in real time, medical professionals can save the lives of many serious patients.

Price & Market Access

Players are making extensive efforts to develop efficient hepatitis b vaccine and hepatitis b medications for the patients. They are participating in R&D activities with help from leading healthcare consulting services provider, Disease Landscape Insights. This health consultant has been supporting them in drug development, treatment gaps identification, clinical trial feasibility analysis, drug launch strategies, price and market access plans, while empowering them with the ideal regularity consulting services as well.

Hepatitis B- A Dreadful Epidemic:

This disease is contagious in nature since it is caused by a virus. Hepatitis B transmission occurs through contact with infected blood or other bodily fluids. Unprotected sex, sharing needs or syringes, sharing personal items like razors or toothbrushes with an infected person, and contact with infected blood through open wounds or cuts increases the risk of infection. It can also be transmitted from an infected mother to her baby during childbirth.

The primary symptoms of this disorder are fatigue, fever, abdominal pain, loss of appetite, nausea, vomiting, dark urine, and clay-colored stools. Also unexplained weight loss, swelling of legs and abdomen, persistent jaundice, and easy bruising are some other signs of Hepatitis B.

Discover More About Pricing and Reimbursement, Epidemiology Study, and Healthcare @

https://www.diseaselandscape.com/downloadsample/postid/4

There is not permanent hepatitis b cure but various drugs and therapies have been developed to alleviate the symptoms. Hepatitis B prevention is also possible with the administration of hepatitis b vaccine.  With growing cognizance about this ailment, the masses are also being educated about the importance of early inoculation. The hepatitis b vaccine price is also being reduced across various nations to make it accessible to people belonging to any section of the society.

Diagnosis And Treatment:

Hepatitis B diagnosis involves a series of tests and examinations. Blood tests like Hepatitis B Surface Antigen, Hepatitis B Surface Antibody, Hepatitis B Core Antibody, and HVB DNA are recommended for accurate detection. Besides, liver function tests, imaging tests, and liver biopsy are also conducted to diagnose this ailment.

The treatment of hepatitis b depends on whether it is an acute or chronic infection and the severity of the disease. Antiviral hepatitis b medications, liver transplant, drugs to alleviate symptoms like digestive issues, and lifestyle changes are generally recommended in the course of treatment.

Unlock the Benefits Today! Get Started Now and Elevate Your Experience @

Checkout_Hepatitis B (acute)

Final Words:

Hepatitis B is a critical illness that leads to liver damage if left undiagnosed and untreated. Many people have lost their lives to this disease. It is contagious in nature and can spread through unprotected sex, close contact with infected person, and syringe sharing, among others. DLI's contributions the hepatitis b management vertical holds the potential to transform how professionals diagnose, treat, and ultimately control this disease. By harnessing DLI's expertise on this disease, players can gain a deeper understanding of the virus and its interactions with potential treatments, paving the way for more effective therapies.

Browse Through More Infectious Diseases Research Reports.

Related Reports:

Addressing Ethical Considerations: Insights & Strategies: Investigating AI's Potential to Transform Radiology: Applications AI in Medical Imagingm

Addressing Ethical Considerations: Insights & Strategies for AI in Healthcare

Top cancer-related causes of death

Paxlovid is recognized as a COVID-19 Breakthrough Therapy with Emergency Use Authorization.

The Top 5 Monkeypox Research Companies and Monkeypox

How Technology is Revolutionizing the Drug Discovery Industry

Treatment, Research, and Leading Companies dealing with lung cancer

Money Is Important: Boosting Clinical Trial Revenue Strategies by Resolving CRO Issues

Dry Eye Disease Is Miebo Treating

Qalsody: A Ground-Breaking Medicine from Biogen Inc.

How Can Clinical Trial Ancillary Management Be Improved to Enhance Research Outcomes?

A Brief History of the Monkeypox Disease Global Market: Taking Advantage of Possibilities for a Healthier Future and Surmounting Obstacles by Providing Hope for Lupus Disease Research

Overcoming Obstacles by Presenting Hope in Lupus Disease Research

Diabetes Treatment Without Needles: Diagnostic Advances and Market Change

Manufacturing Barriers for Early Pancreatic Cancer Detection Kit Manufacturers: Understanding the Maze

Creating the Future of Pneumonia Treatment Options is boosting market growth.

A Game-Changer for the Management of Patients with Ovarian Cancer: Inhibitors of PARP

Managing the Alzheimer's Landscape: How We Direct Market Participants to Unique Solutions

Healthcare is being revolutionized by AI-driven Personalized Medicine.

New Topical Drug Delivery Therapies Unlock the Future of Skin-Credible Care, Causing a Psoriasis Care Crisis!

About Disease Landscape:  

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

Contact Us:   
Disease Landscape Insights LLP  
6th Floor, Sr No.207, Office A H 6070 Phase 1 
Solitaire Business Hub, Viman Nagar  
Pune, Maharashtra, 411014 
Contact: +44-2038074155
Asia Office Contact: +917447409162
Email: ajay@diseaselandscape.com    
Email: vishal@diseaselandscape.com
Blog: https://www.diseaselandscape.com/blogs  
Case Study: https://www.diseaselandscape.com/casestudies   
Pharma consulting Services  
Follow Us: LinkedIn | Twitter | Facebook

Logo: https://mma.prnewswire.com/media/2217060/4328675/Disease_Landscape_Insights_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.